Format

Send to

Choose Destination
PLoS One. 2014 Mar 5;9(3):e90671. doi: 10.1371/journal.pone.0090671. eCollection 2014.

Differential neuroprotective effects of 5'-deoxy-5'-methylthioadenosine.

Author information

1
Center of Neuroimmunology, Institut d'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS) - Hospital Clinic of Barcelona, Barcelona, Spain.
2
CIMA, Neurosciences Division, University of Navarra, Pamplona, Spain; Oncology Area, Lung Cancer Unit, Center for Biomedical Research of la Rioja (CIBIR), Logroño, Spain.
3
Department of Neurosciences, University of Basque Country, Achucarro Basque Center for Neuroscience, Leioa, Spain; Institute of Neurobiology, Slovak Academy of Sciences, Kosice, Slovak Republic.
4
Department of Neurosciences, University of Basque Country, Achucarro Basque Center for Neuroscience, Leioa, Spain; Institute of Neurobiology, Slovak Academy of Sciences, Kosice, Slovak Republic; Centro de Investigaciones Biomédicas en red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
5
Department of Neurosciences, University of Basque Country, Achucarro Basque Center for Neuroscience, Leioa, Spain.
6
Centro de Investigaciones Biomédicas en red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Cellular Biology, Immunology and Neurosciences, Medicine School, University of Barcelona, Barcelona, Spain.
7
Department of Neurology, University of Michigan Medical Center, Ann Arbor, Michigan, United States of America.
8
Institute for Research in Biomedicine (IRB), Barcelona, Spain.
9
Universidad de Castilla la Mancha, Albacete, Spain.
10
CIMA, Neurosciences Division, University of Navarra, Pamplona, Spain.
11
CIMA, Neurosciences Division, University of Navarra, Pamplona, Spain; Oncology Area, Lung Cancer Unit, Center for Biomedical Research of la Rioja (CIBIR), Logroño, Spain; Department of Neurosciences, University of Basque Country, Achucarro Basque Center for Neuroscience, Leioa, Spain; Institute of Neurobiology, Slovak Academy of Sciences, Kosice, Slovak Republic; Centro de Investigaciones Biomédicas en red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain; Department of Cellular Biology, Immunology and Neurosciences, Medicine School, University of Barcelona, Barcelona, Spain; Department of Neurology, University of Michigan Medical Center, Ann Arbor, Michigan, United States of America; Institute for Research in Biomedicine (IRB), Barcelona, Spain; Universidad de Castilla la Mancha, Albacete, Spain; Department of Biochemistry and Molecular Biology, School of Biology, University of Barcelona, Barcelona, Spain.

Abstract

BACKGROUND:

5'-deoxy-5'-methylthioadenosine (MTA) is an endogenous compound produced through the metabolism of polyamines. The therapeutic potential of MTA has been assayed mainly in liver diseases and, more recently, in animal models of multiple sclerosis. The aim of this study was to determine the neuroprotective effect of this molecule in vitro and to assess whether MTA can cross the blood brain barrier (BBB) in order to also analyze its potential neuroprotective efficacy in vivo.

METHODS:

Neuroprotection was assessed in vitro using models of excitotoxicity in primary neurons, mixed astrocyte-neuron and primary oligodendrocyte cultures. The capacity of MTA to cross the BBB was measured in an artificial membrane assay and using an in vitro cell model. Finally, in vivo tests were performed in models of hypoxic brain damage, Parkinson's disease and epilepsy.

RESULTS:

MTA displays a wide array of neuroprotective activities against different insults in vitro. While the data from the two complementary approaches adopted indicate that MTA is likely to cross the BBB, the in vivo data showed that MTA may provide therapeutic benefits in specific circumstances. Whereas MTA reduced the neuronal cell death in pilocarpine-induced status epilepticus and the size of the lesion in global but not focal ischemic brain damage, it was ineffective in preserving dopaminergic neurons of the substantia nigra in the 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP)-mice model. However, in this model of Parkinson's disease the combined administration of MTA and an A2A adenosine receptor antagonist did produce significant neuroprotection in this brain region.

CONCLUSION:

MTA may potentially offer therapeutic neuroprotection.

PMID:
24599318
PMCID:
PMC3944389
DOI:
10.1371/journal.pone.0090671
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center